<DOC>
	<DOCNO>NCT02638389</DOCNO>
	<brief_summary>The phosphatidylinositol 3-kinase ( PI3Kinase ) /Protein Kinase B ( AKT ) /mammalian target rapamycin ( mTor ) pathway play role development venous/lymphatic vascular organisation . The investigator want study efficacy safety Rapamycin , mTor inhibitor .</brief_summary>
	<brief_title>Efficacy Safety Sirolimus Vascular Anomalies That Are Refractory Standard Care</brief_title>
	<detailed_description>The complex vascular malformation induce chronical pain organic dysfunction cause significant morbidity mortality . Therefore , investigator need establish guideline order treat pathology . Standard treatments surgery interventional radiology limit efficacy related high level recurrence well complication . Recent preclinical study show important role PI3Kinase/AKT/mTor pathway development venous/lymphatic vascular organisation suggest appeal therapeutic target treat patient venous , lympathic complex vascular malformation . Investigators realize multicentric phase III study enrol high number patient statistically evaluate efficacy safety Rapamycin , mTOR inhibitor , treatment child adult vascular malformation conventional therapy surgery sclerotherapy ineffective associate high risk important complication . Nearly 250 patient ( 200 adult 50 child ) enrol several european center .</detailed_description>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Vascular Malformations</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients complex vascular anomaly refractory standard care medical treatment , surgical resection and/or sclerotherapy/embolization ( ineffective accompany major complication ) Patients must adequate medullary function : Hemoglobine &gt; 10,0 g/dl , neutrophils &gt; 1500/mm³ platelet &gt; 100.000/mm³ Patients must follow laboratory value : Total serum bilirubin ≤ 1.5 x ULN ( totally bilirubin ≤ 3 x ULN direct bilirubin ≤ 1.5 x ULN patient well document Gilbert Syndrome ) Serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 x ULN ( &lt; 5.0 x ULN hepatic metastasis present ) Serum creatinine 1.5 x ULN . If serum creatinine ≥ 1.5 x ULN , 24hour Creatinine Clearance must conduct result must ≥ 60 mL/min . Karnofsky &gt; 50 Patients able sign inform consent Women age procreation inform contraceptive method mandatory study time Any follow concurrent severe and/or uncontrolled medical condition , could compromise participation study interfere study result : Impaired cardiac function clinically significant cardiac disease , include unstable angina pectoris , ventricular arrhythmia , valvular disease document compromise cardiac function , myocardial infarction within last 6 month , document persistent elevated cardiac enzyme persistent regional wall abnormality assessment LVEF function , history document congestive heart failure ( New York Heart Association functional classification IIIIV ) , document cardiomyopathy , family history congenital long short QT , know history QT/QTc prolongation Torsades de Pointes ( TdP ) Impairment GastroIntestinal ( GI ) function GI disease may significantly alter absorption sirolimus ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea ≥ Grade 2 , malabsorption syndrome , small bowel resection ) Known hypersensitivity drug metabolites similar class study treatment . Patient concurrent severe /or uncontrolled medical condition would , investigator 's judgment , contraindicate participation clinical study ( e.g . acute chronic pancreatitis , liver cirrhosis , active chronic hepatitis , severely impaired lung function spirometry ≤ 50 % normal predict value and/or O2 saturation ≤ 88 % rest , etc . ) Immunocompromised patient , include know seropositivity HIV Pregnant lactate woman Prior treatment PI3K and/or mTOR inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>